Literature DB >> 10417679

Villous tumor of the colon and rectum with special reference to roles of p53 and bcl-2 in adenoma-carcinoma sequence.

T Yao1, M Kajiwara, T Kouzuki, A Iwashita, M Tsuneyoshi.   

Abstract

Villous tumors are rare and their histological diagnosis from biopsy specimens is often difficult. To ascertain its tumor progression, including the genetic events, would be useful for clinical treatment. Clinicopathological features and the expression of p53 and bcl-2 proteins were investigated in 50 villous tumors from 49 patients. The patients' ages ranged widely from 32 to 84 years (average, 61 years). Females were more frequently affected than males (male:female ratio, 20:29). Thirty-six (72%) of the villous tumors were present within the sigmoid colon and rectum. Histologically, 17 (34%) of these contained carcinomas in villous adenomas (CIVA), while 24 (73%) of 33 villous adenomas (VA) contained high-grade dysplasia. Most of the CIVA revealed well-differentiated adenocarcinoma, often with focal or diffuse mucin pools. Three lesions of invasive carcinomas were composed of extremely well-differentiated components. The average size of the CIVA (79 mm) was significantly larger than that of the VA (51 mm). Overexpression of p53 protein was recognized in 12% of VA, in 24% of mucosal components of CIVA and in 18% of invasive components of CIVA. Overexpression of bcl-2 was recognized in 57% of VA, 33% of mucosal components of CIVA, and 7% of invasive components of CIVA. Several characteristic features were recognized in villous tumors, which comprised: (i) a high frequency of coexistence of carcinoma; (ii) multiple foci of carcinomas arising in adenomatous tumors; (iii) a lower histological grade of carcinomas, often with mucin pools; (iv) the existence of extremely well-differentiated adenocarcinomas; and (v) less frequent expression of p53 protein in the carcinomatous components. According to these findings, the pathway of tumor progression in the villous tumors is possibly different from that of sporadic colorectal carcinomas. Because of the peculiarity of villous tumors, careful clinical management is required.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10417679     DOI: 10.1046/j.1440-1827.1999.00881.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  5 in total

1.  Adenoma-like adenocarcinoma: a subtype of colorectal carcinoma with good prognosis, deceptive appearance on biopsy and frequent KRAS mutation.

Authors:  Raul S Gonzalez; Justin M M Cates; Mary Kay Washington; Robert Daniel Beauchamp; Robert J Coffey; Chanjuan Shi
Journal:  Histopathology       Date:  2015-06-04       Impact factor: 5.087

2.  p53 Nuclear accumulation and Bcl-2 expression in contiguous adenomatous components of colorectal adenocarcinomas predict aggressive tumor behavior.

Authors:  Chandrakumar Shanmugam; Venkat R Katkoori; Nirag C Jhala; William E Grizzle; Gene P Siegal; Upender Manne
Journal:  J Histochem Cytochem       Date:  2007-12-10       Impact factor: 2.479

3.  Immunohistochemical evaluation of tissue-specific proteolytic enzymes in adenomas containing foci of early carcinoma: correlations with cathepsin D expression and other malignant features.

Authors:  Toshiaki Kunimura; Tomoko Inagaki; Masahiro Wada; Jun Ushio; Kasumi Sato; Tetsuji Enosawa; Masanao Nakashima; Hirotaka Kato; Ryouji Hayashi; Kouji Saitou; Toshio Morohoshi
Journal:  Int J Gastrointest Cancer       Date:  2003

4.  Advanced colorectal polyps with the molecular and morphological features of serrated polyps and adenomas: concept of a 'fusion' pathway to colorectal cancer.

Authors:  J R Jass; K Baker; I Zlobec; T Higuchi; M Barker; D Buchanan; J Young
Journal:  Histopathology       Date:  2006-08       Impact factor: 5.087

5.  Adenoma-like adenocarcinoma: clinicopathologic characterization of a newly recognized subtype of colorectal carcinoma.

Authors:  Iván A González; Philip S Bauer; Jingxia Liu; Deyali Chatterjee
Journal:  Hum Pathol       Date:  2020-09-28       Impact factor: 3.466

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.